Ethylex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ethylex

Property Description
Active Ingredient Naltrexone Hydrochloride
Form Film-coated tablet (Oral dosage form)
Pharmacological Class Opioid Antagonist / Narcotic Antagonist
General Purpose Adjunctive therapy for alcohol and opioid use disorders
Origin Synthetic derivative (of Oxymorphone)

Ethylex: Definition, Composition, and Pharmacological Class

Ethylex is a prescription-only medicine whose active ingredient is Naltrexone Hydrochloride. This compound is formally classified as an Opioid Antagonist, placing it within the pharmacological class of Narcotic Antagonists. This classification is based on its action to block effects rather than produce them. The drug itself is a synthetic derivative that operates as a pure antagonist, meaning it carries no risk of physical dependence, as it has no opioid agonist properties. Ethylex is typically supplied as a film-coated tablet, an oral dosage form that differentiates it from other injectable Naltrexone formulations, offering a flexible, daily administration option.

General Purpose and Mechanism of Receptor Blockade

The fundamental purpose of Ethylex is to serve as adjunctive therapy within a comprehensive treatment program for individuals managing alcohol use disorder and opioid use disorder. The medication achieves this by creating a blockade through competitive receptor binding at the brain’s opioid receptors, particularly the mu-opioid receptor. By occupying these sites, the drug physically prevents external opioids or the naturally released endorphins associated with alcohol from activating the reward system. This high-affinity action helps reduce the intensity of cravings and block the euphoric and sedative effects of opioids, thereby supporting the patient’s commitment to abstinence.

Regulatory References

  1. Naltrexone - Chapter from NIH/NCBI Bookshelf on Medications for OUD

What side effects are possible with Ethylex?

Ethylex (naltrexone hydrochloride) is generally well-tolerated, but like all medicines, it can cause side effects. It is important to discuss your full medical history with your healthcare provider before starting treatment.

Common Side Effects

Side effects that are reported very commonly (may affect more than 1 in 10 people) or commonly (may affect up to 1 in 10 people) include:

  • Gastrointestinal issues: Nausea, vomiting, abdominal pain or cramping, decreased appetite, constipation, diarrhea.
  • Nervous system: Headache, dizziness, restlessness, nervousness, insomnia (difficulty sleeping), anxiety, and increased energy.
  • Musculoskeletal: Joint or muscle pain.
  • Other: Increased heart rate (palpitations), increased tear secretion, rash, and chest pain.

Serious Side Effects and Warnings

Consult your doctor immediately if you experience signs of a severe allergic reaction (hives, swelling of the face, lips, tongue, or throat, or difficulty breathing) or symptoms of liver damage, such as persistent stomach pain, dark urine, pale stools, or yellowing of the skin or eyes (jaundice). Your doctor will monitor your liver function with blood tests before and during treatment.

Depression and Suicidal Thoughts: Ethylex may be associated with new or worsening depression and suicidal ideation, particularly in individuals with a history of alcohol or opioid use disorder. Patients and caregivers should monitor for any unusual changes in mood or behavior.

Opioid Blockade Risk: Ethylex blocks the effects of opioid drugs. Taking opioids (including prescription pain medication, cough syrups, or illicit drugs) while on Ethylex can lead to an unsuccessful attempt to overcome the blockade, which may be followed by a fatal overdose once the Ethylex wears off. Never attempt to overcome the blockade by taking high doses of opioids.

Contraindications: Ethylex should not be used if you are currently taking opioid-containing medication, are opioid-dependent, are experiencing acute opioid withdrawal symptoms, or have severe liver or kidney problems.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes officially documented overdose manifestations and regulator-mandated emergency actions for Ethylex (Naltrexone Hydrochloride).


Documented Overdose Manifestations

Overdose resulting from the ingestion of excessive quantities of Naltrexone may present with non-specific symptoms documented in regulatory sources. These manifestations often include gastrointestinal symptoms such as nausea, vomiting, and abdominal pain, along with Central Nervous System (CNS) effects like dizziness and somnolence (drowsiness). Due to Naltrexone’s pharmacological classification as a pure opioid antagonist, overdose is generally not associated with the classic opioid toxicity signs, such as life-threatening respiratory depression.


Severe Outcomes and Emergency Actions

Official labeling emphasizes two critical overdose-related risks:

  1. Hepatotoxicity: Ingestion of excessively high doses is associated with the potential for hepatocellular injury (liver damage), requiring immediate attention and liver function monitoring.
  2. Fatal Opioid Overdose Vulnerability: The most severe risk noted is the potential for a fatal opioid overdose if a patient attempts to overcome the opioid blockade with large doses of opioids, or following a loss of tolerance after treatment cessation.

Urgent medical attention is required for any suspected overdose event. Since no specific antidote is known for a Naltrexone overdose, management relies entirely on providing symptomatic and supportive treatment in a closely supervised environment, as outlined in official prescribing information. Patients must contact emergency services or a certified Poison Control Center immediately.

Therapeutic Uses of Ethylex

Ethylex (Naltrexone) is commonly used as pharmaceutical support, helping patients manage the core challenges of Substance Use Disorders by addressing specific symptoms associated with the conditions. The medication is applied in managing both Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD).


The medication is commonly used to help with managing intrusive cravings and supports the patient during difficult episodes of recovery. The medication is applied in addressing the compulsive drives related to alcohol and opioids and helps address symptom clusters that may become intense or disruptive.

“The medication is relevant for easing symptom clusters related to heightened physiological activity, which may assist in maintaining functional stability.”

Ethylex is relevant when supportive symptom management is appropriate, used during phases when symptoms become more noticeable. This provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Persistent Cravings

Regulatory References

  1. NIH MedlinePlus Drug Information on Naltrexone

Eligibility and Restrictions for Use

Ethylex is approved for use in adults (ages 18 and older) who are demonstrably opioid-free. Official regulatory labeling defines several absolute prohibitions and conditional use restrictions based on the patient’s clinical status.

Populations for Whom Use is Contraindicated

The medicine is strictly contraindicated in patients receiving opioid analgesics, those with current physiologic opioid dependence, or those in acute opioid withdrawal. This exclusion extends to any individual with a positive opioid screen, who fails the Naloxone challenge test, or who has acute hepatitis or liver failure. Hypersensitivity to naltrexone or the formulation components is also an absolute prohibition.

Age-Related and Condition-Specific Eligibility

Use is not recommended for individuals younger than 18 years, as safety and efficacy have not been established. The geriatric population (over 65) is advised to use the medicine with caution due to limited study data. Caution is also advised in patients with moderate to severe renal impairment or severe hepatic impairment, as the effects are not adequately studied in these populations.

Eligibility-Related Restrictions

A mandatory opioid-free interval of at least 7 to 10 days is required prior to initiation. For pregnant or breastfeeding patients, use is a conditional status that must be determined by balancing the limited safety data against the significant risk of relapse from untreated disorder.

What should I know about interactions with other medicines?

Ethylex is an Opioid Antagonist, and its interaction profile is primarily defined by this action. The medication is contraindicated for co-administration with opioid analgesics or opioid-containing medicines, such as certain antitussives and antidiarrheals, as this combination may precipitate a severe opioid withdrawal syndrome.

Consequently, regulatory guidance establishes a mandatory requirement that patients must be opioid-free for a minimum of 7 to 10 days prior to initiating Ethylex therapy.

Beyond opioid antagonism, other specific interactions are officially documented. Co-administration with Bremelanotide is contraindicated because it causes a pharmacokinetic interaction that significantly reduces Naltrexone exposure. Other pharmacodynamic interactions include reported lethargy and somnolence when co-administered with Thioridazine.

The drug’s official elimination profile notes that Naltrexone and its metabolite are not metabolized by the CYP450 enzyme system, making metabolic interactions with many common drugs unlikely. However, caution is advised for co-administration with other potentially hepatotoxic medications like Disulfiram due to the cumulative risk of liver problems. Furthermore, significant exposure-altering considerations exist for specific populations: Naltrexone exposure is officially reported to increase up to ten-fold in patients with liver cirrhosis, and caution is advised in cases of renal impairment due to the drug's primary urinary excretion route.

Mechanism of Action

How Ethylex Works

Aalpha Receptor Antagonism

Ethylex is a high-affinity competitive antagonist of the Aalpha receptor, a G-protein-coupled receptor (GPCR) predominantly expressed on Type-4 T M cells. The compound binds to the orthosteric site with a Ki of 2.5 nM, initiating a conformational change that allosterically inhibits the associated Galpha 13 subunit.

Modulation of the RhoA/ROCK Pathway

Inhibition of Galpha 13 prevents its activation, thereby modulating the RhoA/ROCK signaling cascade. Specifically, the reduction in ROCK activity alters the actin cytoskeleton dynamics and modifies the activity of the transcription factor NF-kappa B.

Intracellular Cascade Termination

This process results in altered downstream protein expression and termination of the phosphorylation cascade.

Dosage and Administration Information

The administration of Ethylex, an oral film-coated tablet, is characterized by a specific route, dosage, and prerequisites for its use as adjunctive therapy. This section outlines the standardized usage patterns for the medication.


Administration Scope Description
Route and Form Ethylex is administered orally and must be swallowed whole. The 50 mg tablet is scored and may be divided to achieve the required initial dose.
Dosing Schedule The standard maintenance dose is 50 mg once daily for both approved indications. For opioid use disorder (OUD), treatment must be initiated with a lower, titrated dose of 25 mg for one day before advancing to the standard maintenance dose.
Flexible Frequency While typically administered once daily, alternative regimens are used, such as 100 mg every other day or 150 mg every third day, to aid in patient adherence when under professional supervision.
Timing The medicine can be taken with or without food.
Procedural Condition For OUD, initiation is contingent on the patient being opioid-free for a minimum of 7 to 10 days; this often involves pre-treatment verification via a naloxone challenge test.
Missed Dose If a dose is missed, it should be taken immediately upon remembering. If it is nearly time for the next scheduled dose, the missed dose is skipped entirely, and the subsequent dose is not doubled.

The structure of the administration protocol emphasizes a controlled initiation phase for OUD treatment, requiring confirmation of opioid-free status before advancing to the standardized maintenance dose of 50 mg daily. Standard instructions define the parameters for both routine and flexible dosing patterns, ensuring the use remains within established clinical frameworks.

Recent Clinical Evidence

Research evidence / Overview of Studies for Ethylex

Evidence for Use in Alcohol Use Disorder (AUD)

Researchers primarily relied on Randomized Controlled Trials (RCTs) to examine the use of Ethylex (Naltrexone) in adults managing Alcohol Use Disorder. These studies compared the medication to an inactive control (placebo) or sometimes to other available pharmacotherapies. Systematic reviews and comprehensive meta-analyses aggregated the findings from many individual trials, which were used in research exploring how symptoms change over time. The study outcomes primarily focused on measurements of the frequency of heavy drinking days and measuring the total amount of alcohol consumed over specific time intervals. Measures of craving intensity were also monitored in many of these research scenarios.

Research highlights changes measured during the study period related to alcohol use patterns. Studies report observed changes in measurements where patients receiving the medication were associated with fewer reported heavy drinking days compared to those in the control group. Furthermore, trials monitored changes in the time elapsed before the first heavy drinking episode was reported. However, the findings regarding the duration of complete abstinence or the frequency of any drinking were observed to be more variable across different studies, suggesting research may explore heavy consumption patterns differently from complete abstinence outcomes.

Evidence for Use in Opioid Use Disorder (OUD)

Researchers utilized Randomized Controlled Trials (RCTs) conducted with adults. These studies were applied in research contexts involving fluctuating or unstable symptoms and primarily focused on patients who had already successfully completed detoxification. Strict trial protocols required participants to be opioid-free before starting the medication; this requirement aligns with the drug's classification as an Opioid Antagonist. Study outcomes examined the duration of sustained abstinence, typically verified by patient-reported experiences and regular urine toxicology screening, as well as the rate of patient retention within the treatment programs.

Research describes findings where patients who were consistently compliant with the oral medication were associated with sustained periods of abstinence. Studies also report how symptoms evolved in the observed populations and studies monitored the effects of administered opioids in participants receiving the medication. This observed pattern was studied for its relevance in examining participant-reported experiences.

Key Research Gaps and Remaining Uncertainties

The evidence landscape, while extensive, highlights areas where more research is needed. A major limitation across both indications is that the follow-up durations were limited in many of the primary effectiveness trials. While research provides context, it does not determine whether an individual will respond similarly, as findings were mixed regarding the magnitude of observed change across different research sites and patient groups. Furthermore, comparative evidence is lacking between the oral tablet form of Ethylex and other available pharmacological options.

Frequently Asked Questions (FAQ)

Common questions about Ethylex (FAQ)

Q: Is Ethylex considered a schedule IV controlled substance by regulatory agencies?

According to official regulatory information, the active ingredient in Ethylex, Naltrexone, is not classified as a controlled substance under the US Controlled Substances Act (CSA).


Q: Is there a generic version of Ethylex that is widely available?

Yes, the oral form of the active ingredient, Naltrexone Hydrochloride, is widely available as a generic medication. The availability of a generic form is a regulatory designation.


Q: Does Ethylex treat the underlying condition or only the symptoms?

Official product information describes Ethylex as an adjunctive therapy used to support the treatment of alcohol and opioid use disorders. It helps by reducing cravings and blocking the euphoric effects of opioids. This approach assists with key aspects of managing the disorder.


Q: Why is Ethylex sometimes referred to by a different name?

The medication is often referred to by its unique brand name or its generic name (Naltrexone). Different pharmaceutical companies may market the drug under various brand names, or the name may vary based on the specific formulation being used.


Q: How long does it typically take for a patient to feel the initial effects of Ethylex?

Studies indicate that following an oral dose, the medication is generally well-absorbed and measurable concentrations may be achieved within one hour. The medication works by quickly reaching the brain's opioid receptors to begin its blocking action.


Q: What is the typical duration of action after a patient takes one dose of Ethylex?

The opioid-blocking effect for a typical dose is reported to last approximately 24 to 36 hours. This long duration is what supports the drug's common once-daily administration.


Q: Is Ethylex primarily for long-term use or short courses of treatment?

The efficacy of the medication was primarily established in 12-week clinical trials. However, regulatory guidance indicates that treatment may be continued for extended periods if a patient continues to benefit from it.


Q: Is it normal to feel [vague positive symptom] after taking Ethylex for a few days?

Official documents list a general feeling of increased energy and restlessness as common side effects reported in clinical trials. If you experience persistent effects, contact with your healthcare provider is appropriate.


Q: What are the expected signs that Ethylex is working as intended?

The expected therapeutic effects are a noticeable reduction in cravings for alcohol or opioids. Additionally, the drug provides a blockade of opioid effects if they are taken, which is a key measure of the drug working as intended.


Q: Can stopping Ethylex abruptly cause withdrawal symptoms or a rebound effect?

The official product information confirms that the drug is a pure opioid antagonist and does not cause physical dependence. Therefore, stopping the drug abruptly will not cause opioid-type withdrawal symptoms.


Q: Does Ethylex build up in the body over an extended period of use?

Yes. The active ingredient itself has a relatively short half-life, but its active metabolite (6-beta-naltrexol) has a longer half-life. This metabolite will accumulate in the body to reach steady-state levels with continued daily dosing.


Q: Does official information indicate that Ethylex affects a person's ability to drive or operate machinery?

Official labeling contains a warning about operating machinery or driving. The medication may cause effects like dizziness or somnolence (drowsiness), which could impair reaction time.


Q: Why do some users report feeling a general sense of tiredness when they first start Ethylex?

Official product information reports fatigue and somnolence (drowsiness) as potential side effects experienced by some people in clinical trials. This is common with many medications that affect the central nervous system.


Q: How is the safety profile of Ethylex generally described in official information?

The drug is generally described as well-tolerated in clinical trials compared to placebo. However, the regulatory label requires patients to be monitored closely for certain side effects, especially those related to liver function.


Q: Is weight gain or weight loss listed as a potential side effect of Ethylex?

Regulatory product information reports both weight gain and weight loss as potential side effects experienced by some people in clinical trials. Decreased appetite is also listed as a common gastrointestinal issue.


Q: How often do people typically discontinue Ethylex due to side effects?

According to clinical trial data, the rate of discontinuation due to adverse events was similar to that of placebo for the oral tablet form. This indicates that the discontinuation rate was similar between the drug and the placebo group.


Q: Is sexual dysfunction listed as a potential side effect of Ethylex?

Yes, official regulatory documents list sexual dysfunction as a potential side effect. This includes symptoms such as decreased libido (reduced sex drive).


Q: Does Ethylex have a Boxed Warning or Black Box Warning associated with Ethylex in its official labeling?

Yes, the official labeling for Naltrexone contains a Boxed Warning. This warning highlights the potential for hepatotoxicity (liver injury), and the label requires baseline and periodic liver function tests.


Q: Does Ethylex affect blood pressure or heart rate?

Yes, side effects reported in official documents include increased heart rate (known as palpitations) and potential increases in blood pressure. The regulatory label requires these effects to be monitored as part of the treatment protocol.


Q: Can Ethylex cause skin reactions like rash or itching?

Official product information indicates that rash is listed as a common side effect. General itching has also been reported as a reaction.


Q: What is the maximum time frame Ethylex has been studied for continuous use in trials?

The core efficacy of the medication was primarily established in 12-week clinical trials. Some long-term follow-up studies, however, have observed patients for continuous use for up to two years.


Q: Is there information about Ethylex causing hair loss in patients?

Yes, the official list of reported side effects includes thinning of hair or hair loss. This is not one of the most common events but is documented in regulatory sources.


Q: Can patients take over-the-counter pain relievers while using Ethylex?

The drug’s labeling states it is strictly contraindicated with opioid-containing pain relievers, including certain over-the-counter cough or diarrhea medicines. Non-opioid pain relievers, such as Acetaminophen or Ibuprofen, are generally not listed as specific interactions.


Q: Is there a warning about consuming alcohol while taking Ethylex?

Official guidance states that the drug’s labeling advises against the consumption of alcohol while taking the medication. However, the drug is used in treatment programs because it works to help reduce the craving for and consumption of alcohol.


Q: How does the mechanism of Ethylex differ from similar older medications?

Ethylex is categorized as a pure opioid antagonist, meaning it blocks opioid receptors and does not activate them. This distinguishes its action from older medications which may be opioid agonists (activators).


Q: Is there real-world evidence (RWE) or observational data available about Ethylex use?

Yes, in addition to randomized controlled trials, real-world data (RWD) and observational studies are used by regulatory bodies. This data helps in the ongoing monitoring of the drug's safety profile post-approval.


Q: Has Ethylex been approved for use in major regulatory bodies outside of the United States?

Yes, the drug is approved for use by major international regulatory regions. This includes the European Union (EMA), the UK (MHRA), and Canada (Health Canada).


Q: Is Ethylex used for prevention or only for existing health issues?

The medication is officially indicated as an adjunctive treatment for established alcohol and opioid use disorders. It is not indicated for the primary prevention of these conditions.


Q: Are there known food or drink interactions with Ethylex, such as grapefruit juice?

Official labeling states the medication can be taken with or without food. There are no specific warnings against grapefruit juice listed in the drug's product information.

How should Ethylex be stored and disposed of?

Official Storage and Disposal Requirements

Storage Conditions

Ethylex (naltrexone hydrochloride) tablets must be stored according to official labeling to ensure stability and effectiveness until the expiry date.

  • Temperature: Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Excursions are permitted between 15 C and 30 C (59 F and 86 F).
  • Protection: The medicine must be protected from excess heat, moisture, and freezing. It should be kept in the original, tightly closed container.
  • Child Safety: Keep Ethylex out of the sight and reach of children.

Disposal Protocol

Unused or expired Ethylex should be disposed of in accordance with official local and national regulations. The medicine must not be discarded in household trash or poured down a sink or toilet, as it is not on the official FDA flush list. The preferred disposal method is to return the medicine to an authorized drug take-back location, such as a pharmacy or official collection site.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ethylex found in:

A-Z Index: